Story perspectives

FDA Approves ZYN Pouches, WHO Warns Youth Surge

7/3/2026

Summary

Story summary

On June 30, the FDA authorized 20 ZYN nicotine pouch products to carry a modified-risk claim.
The claim says the products lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis vs smoking.
The order includes ZYN flavors at 3 mg and 6 mg, the first endorsement of nicotine pouches.
The World Health Organization (WHO) warns nicotine pouch sales hit 23.4 billion units in 2024, outpacing regulation and drawing youth.

1 of 1

Story summary

On June 30, the FDA authorized 20 ZYN nicotine pouch products to carry a modified-risk claim.
The claim says the products lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis vs smoking.
The order includes ZYN flavors at 3 mg and 6 mg, the first endorsement of nicotine pouches.
The World Health Organization (WHO) warns nicotine pouch sales hit 23.4 billion units in 2024, outpacing regulation and drawing youth.